MX343873B - Ensayo de diagnostico de anticuerpo. - Google Patents
Ensayo de diagnostico de anticuerpo.Info
- Publication number
- MX343873B MX343873B MX2013010571A MX2013010571A MX343873B MX 343873 B MX343873 B MX 343873B MX 2013010571 A MX2013010571 A MX 2013010571A MX 2013010571 A MX2013010571 A MX 2013010571A MX 343873 B MX343873 B MX 343873B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody assay
- diagnostic antibody
- diagnostic
- amyloidosis
- diagnosis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161453449P | 2011-03-16 | 2011-03-16 | |
| PCT/EP2012/054629 WO2012123562A1 (en) | 2011-03-16 | 2012-03-16 | Diagnostic antibody assay |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013010571A MX2013010571A (es) | 2013-12-02 |
| MX343873B true MX343873B (es) | 2016-11-25 |
Family
ID=45833428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010571A MX343873B (es) | 2011-03-16 | 2012-03-16 | Ensayo de diagnostico de anticuerpo. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8809508B2 (https=) |
| EP (1) | EP2686346B1 (https=) |
| JP (1) | JP6220675B2 (https=) |
| KR (1) | KR102020072B1 (https=) |
| CN (1) | CN103459421B (https=) |
| AU (1) | AU2012228236B2 (https=) |
| BR (1) | BR112013023211B1 (https=) |
| CA (1) | CA2828433C (https=) |
| DK (1) | DK2686346T3 (https=) |
| EA (1) | EA032054B1 (https=) |
| IL (1) | IL227847A0 (https=) |
| MX (1) | MX343873B (https=) |
| SG (1) | SG192805A1 (https=) |
| WO (1) | WO2012123562A1 (https=) |
| ZA (1) | ZA201305946B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512115B2 (en) | 2013-03-15 | 2016-12-06 | Probiodrug Ag | Inhibitors |
| WO2016097305A1 (en) | 2014-12-19 | 2016-06-23 | Probiodrug Ag | Novel method for the detection of pglu-abeta peptides |
| US10494425B2 (en) * | 2015-02-24 | 2019-12-03 | Rpeptide, Llc | Anti-amyloid-beta antibodies |
| IL256579B2 (en) * | 2015-07-16 | 2023-03-01 | Probiodrug Ag | Human antibodies |
| GB201910697D0 (en) * | 2019-07-26 | 2019-09-11 | Binding Site Group Ltd | Lonisation control |
| US20210096128A1 (en) * | 2019-10-01 | 2021-04-01 | Repligen Corporation | Determination of protein concentration in a fluid |
| KR102790945B1 (ko) * | 2022-09-23 | 2025-04-04 | 경성대학교 산학협력단 | 베타-아밀로이드 42를 이용한 치매 진단 방법 및 이를 이용한 치매 진단 키트 |
| CN121253823A (zh) * | 2025-10-10 | 2026-01-02 | 山东九嘉生物科技有限公司 | 一种用于检测胃蛋白酶原ⅰ的化学发光试剂盒及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| ES2275570T3 (es) * | 1999-12-08 | 2007-06-16 | Intellect Neurosciences, Inc. | Peptidos amiloides beta quimericos. |
| US7117096B2 (en) * | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| CA2487528A1 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| WO2004029629A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| US7304086B2 (en) | 2004-02-05 | 2007-12-04 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| US20100028351A1 (en) | 2006-06-29 | 2010-02-04 | Marc Mercken | Anti-amyloid antibodies, compositions, methods and uses |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| JP5599614B2 (ja) | 2006-11-09 | 2014-10-01 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| EP2091945B1 (en) | 2006-11-09 | 2014-01-15 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| US7803810B2 (en) | 2007-03-09 | 2010-09-28 | Probiodrug Ag | Inhibitors |
| WO2008128983A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Cyano-guanidine derivatives as glutaminyl cyclase inhibitors |
| WO2008128982A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
| JP5675340B2 (ja) | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | 新規阻害剤 |
| JP5675343B2 (ja) | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としての尿素誘導体 |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| JP5676249B2 (ja) | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
| EP2211886A4 (en) * | 2007-10-15 | 2011-07-27 | Centocor Ortho Biotech Inc | HUMAN ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, PROCESSES AND APPLICATIONS |
| AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| EP2320942B1 (en) * | 2008-07-21 | 2018-03-14 | Probiodrug AG | Diagnostic antibody assay |
| WO2010128139A1 (en) * | 2009-05-08 | 2010-11-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment |
| PT2448968T (pt) * | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
-
2012
- 2012-03-16 BR BR112013023211-0A patent/BR112013023211B1/pt not_active IP Right Cessation
- 2012-03-16 EP EP12708855.7A patent/EP2686346B1/en active Active
- 2012-03-16 AU AU2012228236A patent/AU2012228236B2/en not_active Ceased
- 2012-03-16 DK DK12708855.7T patent/DK2686346T3/en active
- 2012-03-16 CA CA2828433A patent/CA2828433C/en active Active
- 2012-03-16 KR KR1020137023118A patent/KR102020072B1/ko not_active Expired - Fee Related
- 2012-03-16 JP JP2013558453A patent/JP6220675B2/ja not_active Expired - Fee Related
- 2012-03-16 US US13/422,583 patent/US8809508B2/en active Active
- 2012-03-16 WO PCT/EP2012/054629 patent/WO2012123562A1/en not_active Ceased
- 2012-03-16 EA EA201301029A patent/EA032054B1/ru not_active IP Right Cessation
- 2012-03-16 SG SG2013062286A patent/SG192805A1/en unknown
- 2012-03-16 MX MX2013010571A patent/MX343873B/es active IP Right Grant
- 2012-03-16 CN CN201280013607.2A patent/CN103459421B/zh not_active Expired - Fee Related
-
2013
- 2013-08-07 IL IL227847A patent/IL227847A0/en active IP Right Grant
- 2013-08-07 ZA ZA2013/05946A patent/ZA201305946B/en unknown
-
2014
- 2014-05-19 US US14/280,919 patent/US9657089B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2686346B1 (en) | 2016-12-14 |
| BR112013023211B1 (pt) | 2022-11-08 |
| NZ614217A (en) | 2015-12-24 |
| AU2012228236A1 (en) | 2013-10-03 |
| IL227847A0 (en) | 2013-09-30 |
| WO2012123562A1 (en) | 2012-09-20 |
| JP6220675B2 (ja) | 2017-11-01 |
| SG192805A1 (en) | 2013-09-30 |
| US9657089B2 (en) | 2017-05-23 |
| KR102020072B1 (ko) | 2019-11-04 |
| US20140255414A1 (en) | 2014-09-11 |
| CN103459421B (zh) | 2017-07-14 |
| MX2013010571A (es) | 2013-12-02 |
| US8809508B2 (en) | 2014-08-19 |
| EA032054B1 (ru) | 2019-04-30 |
| KR20140006019A (ko) | 2014-01-15 |
| CN103459421A (zh) | 2013-12-18 |
| US20120237529A1 (en) | 2012-09-20 |
| BR112013023211A2 (pt) | 2016-11-22 |
| CA2828433A1 (en) | 2012-09-20 |
| AU2012228236B2 (en) | 2016-10-27 |
| JP2014509860A (ja) | 2014-04-24 |
| EA201301029A1 (ru) | 2014-05-30 |
| DK2686346T3 (en) | 2017-03-27 |
| CA2828433C (en) | 2020-08-04 |
| EP2686346A1 (en) | 2014-01-22 |
| ZA201305946B (en) | 2014-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010009987A3 (en) | Diagnostic antibody assay | |
| PH12021550083A1 (en) | Human anti-tau antibodies | |
| MX343873B (es) | Ensayo de diagnostico de anticuerpo. | |
| CY1122278T1 (el) | Αντι il-36r αντισωματα | |
| BR112014005644A2 (pt) | anticorpo anti-alfabetatcr | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| PH12015500125A1 (en) | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof | |
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| TN2014000120A1 (en) | Cd27l antigen binding proteins | |
| CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
| MA34091B1 (fr) | Anticorps anti-cd40 | |
| MX345092B (es) | Anticuerpos anti-tau humanos,. | |
| EA030777B9 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
| EA201171388A1 (ru) | Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| MX365387B (es) | Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos. | |
| WO2008136774A8 (en) | Antibodies binding to an intracellular prl-1 or prl-3 polypeptide | |
| ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
| PH12013500432A1 (en) | Anti-vegfr-3 antibody compositions | |
| WO2012144784A3 (ko) | 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도 | |
| AR124605A2 (es) | Anticuerpos anti-il-36r | |
| TN2013000068A1 (en) | Anti-vegfr-3 antibody compositions | |
| TH133365A (th) | แอนติ-N3pGlu อะมัยลอยด์ เบต้าเพปไทด์ แอนติบอดี และการใช้ของมัน | |
| FR2980579B3 (fr) | Procede et kit pour le diagnostic in vitro du cancer du sein | |
| NZ737925A (en) | Monoclonal antibodies against c-met |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |